Navigating Startup Validation in Biologics

In this chapter, the speaker recounts their startup's journey through key milestones in cell-free protein synthesis and antibody production. They discuss the evolution of their machine learning models for predicting binding affinities and strategic partnerships in the biopharmaceutical industry. The narrative highlights the challenges and advancements in creating targeted therapeutics, alongside the necessity of balancing innovation with practical product development.